Parkinson's Disease Pipeline 2026: Emerging Therapies, Clinical Advances, and Key Industry Players

DelveInsight's "Parkinson's Disease Pipeline Insights 2026" Report provides comprehensive insights about 150+ companies and 200+ pipeline drugs in the Parkinson's Disease pipeline landscape. It covers the Parkinson's Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Parkinson's Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Dive into DelveInsight's comprehensive report today! @ Parkinson's Disease Pipeline Report-https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=open&utm_medium=pr&utm_campaign=kkpr

Key Takeaways from the Parkinson's Disease Pipeline Report

• DelveInsight's Parkinson's Disease pipeline report depicts a robust space with 150+ active players working to develop 200+ pipeline therapies for Parkinson's Disease treatment.
• The leading Parkinson's Disease Companies such as Roche, Prothena Biosciences, Annovis Bio, Neuron23, Ventyx Biosciences, Aspen Neuroscience, Lundbeck, Biohaven Pharmaceuticals, Neuraly Inc, FAScinate Therapeutics, Cerevance, Jazz Pharmaceuticals, Sanofi, Eli Lilly and Company, and others.
• Promising Parkinson's Disease Pipeline Therapies such as Prasinezumab, Buntanetap, NEU 411, VTX3232, ANPD001, Lu AF28996, NLY01, CVN424, Mesdopetam, BHV-8000, ENT-01, JZP385, LY4006896, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Parkinson's Disease Treatment Drugs-https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=open&utm_medium=pr&utm_campaign=kkpr

The Parkinson's Disease Pipeline Report provides disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Parkinson's Disease Pipeline Report also highlights the unmet needs with respect to Parkinson's Disease.

Parkinson's Disease Overview

Parkinson's disease is a chronic, progressive neurodegenerative disorder that primarily affects movement and coordination. It results from the gradual loss of dopamine-producing neurons in the brain, leading to characteristic motor and non-motor symptoms. The disease typically develops in older adults and progresses slowly, with symptoms worsening over time. Although not curable, available treatments can effectively manage symptoms and improve quality of life.

Parkinson's disease is caused by a combination of genetic and environmental factors that lead to progressive neuronal damage. Advancing age is the strongest risk factor, while inherited mutations in genes such as SNCA, LRRK2, PARK2, PINK1, and DJ-1 contribute to familial forms of the disease. The disease is characterized by degeneration of dopamine-producing neurons in the substantia nigra pars compacta, resulting in reduced dopamine levels in the nigrostriatal pathway. Additionally, abnormal aggregation of misfolded α-synuclein protein leads to the formation of Lewy bodies, contributing to neuronal dysfunction, inflammation, and progressive neurodegeneration.

Parkinson's disease presents with hallmark motor symptoms such as resting tremor, bradykinesia, muscular rigidity, and postural instability. Non-motor manifestations are common and include depression, anxiety, cognitive impairment, sleep disturbances, autonomic dysfunction, fatigue, and loss of smell.

Parkinson's Disease Emerging Drugs Profile

• Prasinezumab: Roche/Prothena Biosciences
Prasinezumab is an investigational monoclonal antibody designed to bind aggregated alpha-synuclein and thereby reduce neuronal toxicity. By reducing the build-up of alpha-synuclein protein in the brain, prasinezumab can potentially prevent further accumulation and spreading between cells, which may slow progression of the disease. The safety database for prasinezumab consists of data from more than 900 Parkinson's disease study participants that have been treated with the investigational medicine, of which more than 750 remain in open label treatment with over 500 treated for 1.5-5 years. The drug is currently in Phase III stage of clinical trial evaluation to treat Parkinson's disease.
• Buntanetap: Annovis Bio
Buntanetap targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. By improving synaptic transmission, axonal transport, and reducing neuroinflammation, Buntanetap aims to reverse neurodegeneration in Parkinson's disease and other neurodegenerative diseases, thereby restoring brain function and improving the quality of life for patients. The drug is currently in Phase III stage of its clinical development for the treatment of patients with Parkinson's disease.
• NEU 411: Neuron23
NEU 411 is an orally available, brain-penetrant small-molecule inhibitor of the kinase LRRK2, being developed by Neuron23, Inc. for Parkinson's disease. It is designed for the subset of patients with LRRK2-driven PD whether through LRRK2 mutations or predictive SNPs where over activity of LRRK2 is believed to contribute to disease progression. Currently, the drug is in the Phase II stage of its clinical trial for the treatment of Parkinson's disease.
• VTX3232: Ventyx Biosciences
VTX3232 is an oral, brain-penetrant inhibitor of the NLRP3 inflammasome, developed to target neuroinflammation in Parkinson's disease by reducing harmful signaling from microglial activation. It crosses the blood-brain barrier, maintains plasma and cerebrospinal fluid concentrations above the inhibitory threshold for NLRP3, and thereby aims to not only ease motor/non-motor symptoms but modify underlying disease progression. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Parkinson's disease.
• ANPD001: Aspen Neuroscience
ANPD001, developed by Aspen Neuroscience, is an investigational autologous cell-therapy for Parkinson's disease that uses a patient's own skin cells reprogrammed into induced pluripotent stem cells (iPSCs), then differentiated into dopaminergic neuronal precursor cells (DANPCs) for implantation. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Parkinson's disease.
• Lu AF28996: Lundbeck
Lu AF28996 is an investigational small-molecule therapy developed by H. Lundbeck A/S for the treatment of Parkinson's disease. It is designed as a dual dopamine D1 and D2 receptor agonist, providing concerted stimulation of both receptor subtypes to restore dopaminergic signaling and improve motor control in patients with Parkinson's disease. This mechanism of action aims to compensate for dopamine deficiency in the nigrostriatal pathway, thereby alleviating motor symptoms such as bradykinesia and rigidity. Lu AF28996 is formulated for oral administration, typically delivered as a capsule taken once daily. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Parkinson's disease.

The Parkinson's Disease Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson's Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson's Disease Treatment.
• Parkinson's Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Parkinson's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson's Disease market.

Explore groundbreaking therapies and clinical trials in the Parkinson's Disease Pipeline @ New Parkinson's Disease Drugs-https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=open&utm_medium=pr&utm_campaign=kkpr

Parkinson's Disease Companies

Roche, Prothena Biosciences, Biohaven Pharmaceuticals, Neuraly Inc, FAScinate Therapeutics, Cerevance, Hillhurst Biopharmaceuticals, Inc., Endurance Bio, Enterin Inc., Jazz Pharmaceuticals plc, Mthera Pharma Co., Ltd., TrueBinding, IRLAB, Annovis Bio Inc, Neuron23, Forest Hills Lab, Ventyx Biosciences, HanAll Biopharma, Lundbeck, Sanofi, ABL Bio, Contera Pharma, Eli Lilly and Company, Asceneuron SA, Allyx Therapeutics, Inc., Ventus Therapeutics, and others.

Parkinson's Disease Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Parkinson's Disease Products have been categorized under various Molecule types such as:

• Recombinant fusion proteins
• Small molecule
• Monoclonal Antibody
• Peptide
• Polymer
• Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Parkinson's Disease Market Drivers and Barriers-https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=open&utm_medium=pr&utm_campaign=kkpr

Scope of the Parkinson's Disease Pipeline Report

• Coverage- Global
• Parkinson's Disease Companies- Roche, Prothena Biosciences, Annovis Bio, Neuron23, Ventyx Biosciences, Aspen Neuroscience, Lundbeck, Biohaven Pharmaceuticals, Jazz Pharmaceuticals, Sanofi, Eli Lilly and Company, and others.
• Parkinson's Disease Pipeline Therapies- Prasinezumab, Buntanetap, NEU 411, VTX3232, ANPD001, Lu AF28996, NLY01, CVN424, Mesdopetam, BHV-8000, ENT-01, JZP385, LY4006896, and others.
• Parkinson's Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Parkinson's Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Parkinson's Disease Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Parkinson's Disease Companies, Key Products and Unmet Needs-https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=open&utm_medium=pr&utm_campaign=kkpr

Table of Contents

1. Introduction
2. Executive Summary
3. Parkinson's Disease: Overview
4. Comparative Analysis
5. Therapeutic Assessment
6. Parkinson's Disease - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Mid Stage Products (Phase II)
9. Early Stage Products (Phase I)
10. Preclinical and Discovery Stage Products
11. Inactive Products
12. Parkinson's Disease Key Companies
13. Parkinson's Disease Key Products
14. Parkinson's Disease - Unmet Needs
15. Parkinson's Disease - Market Drivers and Barriers
16. Parkinson's Disease - Future Perspectives and Conclusion
17. Parkinson's Disease Analyst Views
18. Appendix

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: kkumar@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.